Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation
- PMID: 6327714
Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation
Abstract
Apolipoprotein (apo-) E3, when combined with the phospholipid dimyristoylphosphatidylcholine (DMPC), binds avidly to apo-B,E (low density lipoprotein) receptors on human fibroblasts. Apolipoprotein E2 isolated from type III hyperlipoproteinemic subjects, which differs from apo-E3 by the presence of cysteine instead of arginine at residue 158, possesses only about 1% of the receptor binding activity of apo-E3. Modification of apo-E2 with cysteamine, which converts the cysteine at position 158 to a positively charged lysine analogue, activates receptor binding approximately 13-fold. In the present experiments, thrombin was used to cleave apo-E2 into two fragments (Mr = 22,000 and Mr = 10,000). The larger fragment, which has been shown to possess the receptor binding domain, displayed binding activity up to 12-fold greater than intact apo-E2 or equivalent to apo-E2 treated with cysteamine. When the Mr = 22,000 fragment was modified with cysteamine and combined with DMPC, receptor binding was further enhanced, attaining the level of activity of normal apo-E3 X DMPC, a 100-fold increase over apo-E2 X DMPC binding. When the cysteamine modification was reversed by incubation with beta-mercaptoethanol, the Mr = 22,000 fragment retained most of its binding activity. However, when the same sample was tested 24 h later, the level of binding activity dropped significantly. The receptor binding of apo-E2-containing beta-very low density lipoproteins could also be activated by cysteamine treatment, with the same retention of enhanced binding activity occurring after the reversal of the modification. These results indicate that apo-E2 can attain full binding activity by the removal of the carboxyl-terminal one-third of the molecule and the addition of a positive charge at residue 158 of the molecule. The retention of enhanced binding after the reversal of the cysteamine modification indicates that the enhanced binding is probably due to conformational changes induced in the binding domain (and maintained by the phospholipid) and not merely to the presence of the positive charge at residue 158.
Similar articles
-
Defective hepatic lipoprotein receptor binding of beta-very low density lipoproteins from type III hyperlipoproteinemic patients. Importance of apolipoprotein E.J Biol Chem. 1984 Jan 25;259(2):860-9. J Biol Chem. 1984. PMID: 6319389
-
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.Proc Natl Acad Sci U S A. 1982 Aug;79(15):4696-700. doi: 10.1073/pnas.79.15.4696. Proc Natl Acad Sci U S A. 1982. PMID: 6289314 Free PMC article.
-
Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype.J Clin Invest. 1983 Oct;72(4):1288-97. doi: 10.1172/JCI111085. J Clin Invest. 1983. PMID: 6313758 Free PMC article.
-
[Apolipoprotein E].Nihon Rinsho. 1994 Dec;52(12):3124-32. Nihon Rinsho. 1994. PMID: 7853700 Review. Japanese.
-
[Human apolipoprotein E: polymorphism and binding domain of the receptors].Biochimie. 1986 May;68(5):629-37. doi: 10.1016/s0300-9084(86)80157-2. Biochimie. 1986. PMID: 3015256 Review. French.
Cited by
-
Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins.Neuron. 2024 Apr 3;112(7):1100-1109.e5. doi: 10.1016/j.neuron.2023.12.018. Epub 2024 Jan 23. Neuron. 2024. PMID: 38266643
-
Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).J Clin Invest. 1995 Aug;96(2):1100-7. doi: 10.1172/JCI118096. J Clin Invest. 1995. PMID: 7635945 Free PMC article.
-
Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.J Clin Invest. 1987 Aug;80(2):483-90. doi: 10.1172/JCI113096. J Clin Invest. 1987. PMID: 3038959 Free PMC article.
-
NMR studies of the low-density lipoprotein receptor-binding peptide of apolipoprotein E bound to dodecylphosphocholine micelles.Protein Sci. 1999 Sep;8(9):1797-805. doi: 10.1110/ps.8.9.1797. Protein Sci. 1999. PMID: 10493581 Free PMC article.
-
The Association between Apolipoprotein E Genotypes and Serum Malondialdehyde Level with End-Stage Renal Disease.Iran J Med Sci. 2023 Jul;48(4):414-419. doi: 10.30476/IJMS.2022.94850.2616. Iran J Med Sci. 2023. PMID: 37456207 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous